Symbols / SRPT $22.80 -1.85% Sarepta Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
SRPT Chart
About

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 2.39B
Enterprise Value 2.54B Income -713.41M Sales 2.20B
Book/sh 10.87 Cash/sh 8.95 Dividend Yield —
Payout 0.00% Employees 835 IPO —
P/E — Forward P/E 7.50 PEG —
P/S 1.09 P/B 2.10 P/C —
EV/EBITDA -4.14 EV/Sales 1.16 Quick Ratio 1.33
Current Ratio 2.32 Debt/Eq 91.14 LT Debt/Eq —
EPS (ttm) -7.13 EPS next Y 3.04 EPS Growth —
Revenue Growth -32.70% Earnings 2026-05-06 ROA -11.24%
ROE -53.47% ROIC — Gross Margin -7.43%
Oper. Margin -92.58% Profit Margin -32.45% Shs Outstand 104.99M
Shs Float 91.78M Short Float 25.26% Short Ratio 10.40
Short Interest — 52W High 64.80 52W Low 10.42
Beta 0.28 Avg Volume 3.00M Volume 2.26M
Target Price $21.65 Recom Hold Prev Close $23.23
Price $22.80 Change -1.85%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.65
Mean price target
2. Current target
$22.80
Latest analyst target
3. DCF / Fair value
$16.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.80
Low
$5.00
High
$38.00
Mean
$21.65

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main Citigroup Sell → Sell $13
2026-03-26 reit Needham Underperform → Underperform —
2026-03-19 reit Oppenheimer Outperform → Outperform $37
2026-03-13 main Mizuho Outperform → Outperform $31
2026-03-10 main Citigroup Sell → Sell $9
2026-03-02 reit HC Wainwright & Co. Sell → Sell $5
2026-02-27 main Wells Fargo Overweight → Overweight $38
2026-01-27 reit HC Wainwright & Co. Sell → Sell $5
2026-01-23 main Wedbush Outperform → Outperform $34
2026-01-14 reit HC Wainwright & Co. Sell → Sell $5
2025-12-09 init Wedbush — → Outperform $32
2025-11-05 main Barclays Equal-Weight → Equal-Weight $20
2025-11-05 main Wells Fargo Overweight → Overweight $45
2025-11-05 main Guggenheim Buy → Buy $19
2025-11-05 up Mizuho Neutral → Outperform $26
2025-11-04 main Baird Neutral → Neutral $15
2025-10-30 main Piper Sandler Neutral → Neutral $16
2025-09-22 up BMO Capital Market Perform → Outperform $50
2025-09-15 reit Guggenheim Buy → Buy $22
2025-09-09 main Leerink Partners Market Perform → Market Perform $15
News
RSS: Latest SRPT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 MAYO STEPHEN L. Director — 7,239 $17.02 $123,208
2026-02-27 RODINO-KLAPAC LOUISE Officer — 8,125 — —
2026-02-27 ESTEPAN IAN MICHAEL Chief Operating Officer — 8,125 — —
2026-02-26 ESTEPAN IAN MICHAEL Chief Operating Officer — 7,450 $13.71 $102,140
2026-01-29 NICAISE CLAUDE M.D. Director — 10,500 $13.71 $143,955
2026-01-27 BEHRENS M KATHLEEN Director — 10,500 $13.71 $143,955
2025-12-16 ESTEPAN IAN MICHAEL Chief Operating Officer — 13,187 $22.31 $294,202
2025-12-05 INGRAM DOUGLAS S Chief Executive Officer — 539,084 $0.00 $0
2025-09-03 RODINO-KLAPAC LOUISE Officer — 143,875 $0.00 $0
2025-09-03 ESTEPAN IAN MICHAEL Chief Operating Officer — 143,875 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,198.24
+15.58%
1,901.98
+52.97%
1,243.34
+33.26%
933.01
Operating Revenue
2,198.24
+15.58%
1,901.98
+52.97%
1,243.34
+33.26%
933.01
Cost Of Revenue
839.61
+163.12%
319.10
+112.25%
150.34
+7.40%
139.99
Reconciled Cost Of Revenue
797.71
+181.10%
283.78
+163.97%
107.50
+8.77%
98.84
Gross Profit
1,358.63
-14.17%
1,582.88
+44.82%
1,092.99
+37.83%
793.02
Operating Expense
2,016.40
+47.74%
1,364.80
+0.29%
1,360.82
+2.38%
1,329.22
Research And Development
1,522.07
+89.19%
804.52
-8.30%
877.39
+0.03%
877.09
Selling General And Administration
491.72
-11.86%
557.87
+15.77%
481.87
+6.75%
451.42
General And Administrative Expense
491.72
-11.86%
557.87
+15.77%
481.87
+6.75%
451.42
Salaries And Wages
229.45
-18.58%
281.80
+9.50%
257.34
-12.42%
293.85
Other Gand A
262.27
-5.00%
276.07
+22.96%
224.53
+42.50%
157.57
Total Expenses
2,856.01
+69.61%
1,683.90
+11.43%
1,511.16
+2.85%
1,469.21
Operating Income
-657.77
-401.62%
218.08
+181.43%
-267.82
+50.05%
-536.20
Total Operating Income As Reported
-699.78
-420.88%
218.08
+181.43%
-267.82
+50.05%
-536.20
EBITDA
-619.56
-295.51%
316.89
+169.85%
-453.69
+23.73%
-594.85
Normalized EBITDA
-578.50
-276.64%
327.51
+1000.55%
-36.37
+92.32%
-473.54
Reconciled Depreciation
44.52
+18.02%
37.72
-15.03%
44.40
+6.05%
41.86
EBIT
-664.09
-337.88%
279.17
+156.05%
-498.09
+21.77%
-636.72
Total Unusual Items
-41.06
-286.53%
-10.62
+97.45%
-417.32
-244.00%
-121.32
Total Unusual Items Excluding Goodwill
-41.06
-286.53%
-10.62
+97.45%
-417.32
-244.00%
-121.32
Special Income Charges
-25.15
-220.83%
-7.84
+98.13%
-418.85
-245.26%
-121.32
Other Special Charges
-16.86
—
387.33
+208.77%
125.44
Impairment Of Capital Assets
—
—
—
—
Restructuring And Mergern Acquisition
42.01
+435.97%
7.84
+553.17%
1.20
+117.91%
-6.70
Write Off
0.00
0.00
-100.00%
30.32
+1077.51%
2.58
Net Income
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Pretax Income
-702.23
-369.28%
260.77
+150.14%
-520.10
+24.62%
-689.96
Net Non Operating Interest Income Expense
-1.45
-102.72%
53.38
-16.55%
63.96
+350.57%
-25.52
Interest Expense Non Operating
38.14
+107.38%
18.39
-16.44%
22.01
-58.67%
53.25
Net Interest Income
-1.45
-102.72%
53.38
-16.55%
63.96
+350.57%
-25.52
Interest Expense
38.14
+107.38%
18.39
-16.44%
22.01
-58.67%
53.25
Interest Income Non Operating
36.69
-48.88%
71.77
-16.52%
85.97
+210.10%
27.72
Interest Income
36.69
-48.88%
71.77
-16.52%
85.97
+210.10%
27.72
Other Income Expense
-43.00
-302.54%
-10.68
+96.62%
-316.23
-146.60%
-128.24
Other Non Operating Income Expenses
-1.94
-3136.67%
-0.06
-100.06%
101.09
+1560.63%
-6.92
Gain On Sale Of Security
-15.91
-471.42%
-2.79
-282.38%
1.53
—
Tax Provision
11.19
-56.20%
25.54
+60.81%
15.88
+17.40%
13.53
Tax Rate For Calcs
0.00
+114.46%
0.00
-53.37%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-8.62
-728.95%
-1.04
+98.81%
-87.64
-244.00%
-25.48
Net Income Including Noncontrolling Interests
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Net Income From Continuing Operation Net Minority Interest
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Net Income From Continuing And Discontinued Operation
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Net Income Continuous Operations
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Normalized Income
-680.97
-378.15%
244.82
+218.68%
-206.29
+66.05%
-607.65
Net Income Common Stockholders
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Diluted EPS
-7.13
-404.70%
2.34
+140.34%
-5.80
+27.77%
-8.03
Basic EPS
-7.13
-388.66%
2.47
+142.59%
-5.80
+27.77%
-8.03
Basic Average Shares
100.12
+5.31%
95.08
+2.90%
92.40
+5.53%
87.56
Diluted Average Shares
100.12
-7.19%
107.88
+16.75%
92.40
+5.53%
87.56
Diluted NI Availto Com Stockholders
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Amortization
2.62
+9.02%
2.40
+54.27%
1.56
+118.35%
0.71
Amortization Of Intangibles Income Statement
2.62
+9.02%
2.40
+54.27%
1.56
+118.35%
0.71
Depreciation Amortization Depletion Income Statement
2.62
+9.02%
2.40
+54.27%
1.56
+118.35%
0.71
Depreciation And Amortization In Income Statement
2.62
+9.02%
2.40
+54.27%
1.56
+118.35%
0.71
Gain On Sale Of PPE
—
—
—
0.00
Securities Amortization
—
—
—
-11.23
Line Item Trend 2025-12-31
Total Assets
3,349.70
Current Assets
2,537.94
Cash Cash Equivalents And Short Term Investments
939.65
Cash And Cash Equivalents
801.28
Other Short Term Investments
138.37
Receivables
519.61
Accounts Receivable
398.23
Other Receivables
104.12
Taxes Receivable
15.60
Accrued Interest Receivable
1.66
Inventory
914.74
Prepaid Assets
154.73
Other Current Assets
9.20
Total Non Current Assets
811.76
Net PPE
470.62
Gross PPE
751.53
Accumulated Depreciation
-280.92
Properties
0.00
Land And Improvements
10.17
Buildings And Improvements
52.23
Machinery Furniture Equipment
73.03
Construction In Progress
5.58
Other Properties
260.81
Leases
349.73
Goodwill And Other Intangible Assets
28.95
Other Intangible Assets
28.95
Investments And Advances
10.57
Other Investments
10.57
Non Current Deferred Assets
2.82
Non Current Deferred Taxes Assets
2.82
Non Current Prepaid Assets
95.95
Other Non Current Assets
202.86
Total Liabilities Net Minority Interest
2,209.08
Current Liabilities
1,095.29
Payables And Accrued Expenses
464.38
Payables
285.60
Accounts Payable
280.84
Current Accrued Expenses
178.78
Pensionand Other Post Retirement Benefit Plans Current
58.61
Total Tax Payable
4.75
Income Tax Payable
4.75
Current Debt And Capital Lease Obligation
11.39
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
11.39
Current Deferred Liabilities
443.40
Current Deferred Revenue
443.40
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
1,113.79
Long Term Debt And Capital Lease Obligation
1,028.35
Long Term Debt
828.97
Long Term Capital Lease Obligation
199.38
Non Current Deferred Liabilities
83.91
Non Current Deferred Revenue
83.91
Other Non Current Liabilities
1.53
Stockholders Equity
1,140.62
Common Stock Equity
1,140.62
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
105.62
Ordinary Shares Number
104.96
Treasury Shares Number
0.65
Additional Paid In Capital
6,042.59
Retained Earnings
-4,876.98
Gains Losses Not Affecting Retained Earnings
0.27
Treasury Stock
25.26
Other Equity Adjustments
0.27
Total Equity Gross Minority Interest
1,140.62
Total Capitalization
1,969.60
Working Capital
1,442.65
Invested Capital
1,969.60
Total Debt
1,039.74
Net Debt
27.69
Capital Lease Obligations
210.77
Net Tangible Assets
1,111.67
Tangible Book Value
1,111.67
Current Provisions
117.52
Interest Payable
20.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-205.48
+0.15%
-205.79
+58.92%
-500.99
-53.99%
-325.35
Cash Flow From Continuing Operating Activities
-205.48
+0.15%
-205.79
+58.92%
-500.99
-53.99%
-325.35
Net Income From Continuing Operations
-713.41
-403.27%
235.24
+143.89%
-535.98
+23.81%
-703.49
Depreciation Amortization Depletion
44.52
+18.02%
37.72
-15.03%
44.40
+6.05%
41.86
Depreciation And Amortization
44.52
+18.02%
37.72
-15.03%
44.40
+6.05%
41.86
Other Non Cash Items
70.59
+1.09%
69.83
+171.25%
-98.01
-607.02%
19.33
Stock Based Compensation
123.40
-33.05%
184.30
+0.98%
182.51
-21.67%
233.02
Asset Impairment Charge
182.30
0.00
-100.00%
30.32
+1077.51%
2.58
Operating Gains Losses
14.38
-40.09%
24.00
-94.04%
403.02
+206.54%
131.48
Gain Loss On Investment Securities
—
7.84
+553.17%
1.20
+117.91%
-6.70
Gain Loss On Sale Of PPE
13.95
-13.71%
16.17
+11.54%
14.49
+13.82%
12.73
Change In Working Capital
78.04
+110.89%
-716.61
-48.95%
-481.09
-1118.87%
-39.47
Change In Receivables
203.75
+201.04%
-201.66
-8.60%
-185.70
-201.27%
-61.64
Changes In Account Receivables
203.75
+201.04%
-201.66
-8.60%
-185.70
-201.27%
-61.64
Change In Inventory
-301.09
+23.81%
-395.17
-167.52%
-147.71
-190.89%
-50.78
Change In Prepaid Assets
78.84
+141.81%
-188.59
-1406.17%
-12.52
-129.42%
42.56
Change In Payables And Accrued Expense
104.27
-5.77%
110.65
+320.70%
-50.13
-133.97%
147.57
Change In Payable
104.27
-5.77%
110.65
+320.70%
-50.13
-133.97%
147.57
Change In Account Payable
104.27
-5.77%
110.65
+320.70%
-50.13
-133.97%
147.57
Change In Other Working Capital
72.05
+324.04%
-32.16
+62.96%
-86.83
+2.71%
-89.24
Change In Other Current Assets
-79.78
-724.56%
-9.68
-635.18%
1.81
+106.47%
-27.94
Investing Cash Flow
69.64
-90.78%
755.56
+555.70%
-165.80
+84.16%
-1,046.88
Cash Flow From Continuing Investing Activities
69.64
-90.78%
755.56
+555.70%
-165.80
+84.16%
-1,046.88
Net PPE Purchase And Sale
-101.97
+25.54%
-136.96
-79.95%
-76.11
-146.91%
-30.82
Purchase Of PPE
-101.97
+25.54%
-136.96
-79.95%
-76.11
-146.91%
-30.82
Capital Expenditure
-109.85
+25.25%
-146.96
-68.25%
-87.34
-170.83%
-32.25
Net Investment Purchase And Sale
5.39
-99.40%
902.52
+600.13%
-180.46
+82.21%
-1,014.63
Purchase Of Investment
-290.48
+73.58%
-1,099.60
+46.33%
-2,048.94
-5.73%
-1,937.86
Sale Of Investment
295.87
-85.22%
2,002.11
+7.15%
1,868.48
+102.39%
923.22
Net Business Purchase And Sale
174.09
0.00
0.00
—
Purchase Of Business
—
—
—
—
Net Intangibles Purchase And Sale
-7.88
+21.24%
-10.00
+11.02%
-11.24
-687.60%
-1.43
Purchase Of Intangibles
-7.88
+21.24%
-10.00
+11.02%
-11.24
-687.60%
-1.43
Net Other Investing Changes
—
—
102.00
+4302.72%
-2.43
Financing Cash Flow
-168.34
-234.88%
124.81
-0.16%
125.00
-46.24%
232.51
Cash Flow From Continuing Financing Activities
-168.34
-234.88%
124.81
-0.16%
125.00
-46.24%
232.51
Net Issuance Payments Of Debt
-162.59
-239000.00%
-0.07
0.00
-100.00%
304.17
Issuance Of Debt
—
0.00
0.00
-100.00%
1,127.40
Repayment Of Debt
-162.59
-239000.00%
-0.07
0.00
+100.00%
-823.23
Long Term Debt Issuance
—
0.00
0.00
-100.00%
1,127.40
Long Term Debt Payments
-162.59
-239000.00%
-0.07
0.00
+100.00%
-823.23
Net Long Term Debt Issuance
-162.59
-239000.00%
-0.07
0.00
-100.00%
304.17
Net Common Stock Issuance
-5.01
0.00
0.00
0.00
Common Stock Payments
-25.01
0.00
0.00
—
Repurchase Of Capital Stock
-25.01
0.00
0.00
—
Proceeds From Stock Option Exercised
18.70
-85.02%
124.87
-5.32%
131.89
+285.91%
-70.94
Net Other Financing Charges
-19.45
—
-6.89
-861.87%
-0.72
Changes In Cash
-304.18
-145.09%
674.58
+224.51%
-541.79
+52.46%
-1,139.72
Beginning Cash Position
1,118.59
+151.93%
444.01
-54.96%
985.80
-53.62%
2,125.52
End Cash Position
814.41
-27.19%
1,118.59
+151.93%
444.01
-54.96%
985.80
Free Cash Flow
-315.33
+10.61%
-352.74
+40.04%
-588.34
-64.53%
-357.60
Interest Paid Supplemental Data
14.91
-5.95%
15.86
-0.42%
15.92
-64.15%
44.42
Income Tax Paid Supplemental Data
37.63
+66.61%
22.59
+49.77%
15.08
+789.73%
1.70
Amortization Of Securities
-5.29
+86.86%
-40.28
+12.78%
-46.18
-333.54%
-10.65
Common Stock Issuance
20.00
0.00
0.00
0.00
Earnings Losses From Equity Investments
17.29
0.00
0.00
—
Issuance Of Capital Stock
20.00
0.00
0.00
0.00
Sale Of Business
174.09
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category